{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:31:44Z","timestamp":1791271904712,"version":"4.1.0"},"reference-count":49,"publisher":"American Association for Cancer Research (AACR)","issue":"10","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Melanomas and other cancers that do not express argininosuccinate synthetase (AS), the rate-limiting enzyme for arginine biosynthesis, are sensitive to arginine depletion with pegylated arginine deiminase (ADI-PEG20). However, ADI resistance eventually develops in tumors because of AS upregulation. Although it has been shown that AS upregulation involves c-Myc, the underlying mechanisms remain unknown. Here we show that ADI-PEG20 activates Ras signaling and the effector extracellular signal\u2013regulated kinase (ERK) and phosphoinositide 3-kinase (PI3K)\/AKT\/GSK-3\u03b2 kinase cascades, resulting in phosphorylation and stabilization of c-Myc by attenuation of its ubiquitin-mediated protein degradation mechanism. Inhibition of the induced cell signaling pathways using PI3K\/AKT inhibitors suppressed c-Myc induction and enhanced ADI-mediated cell killing. Notably, in an animal model of AS-negative melanoma, combination therapy using a PI3K inhibitor plus ADI-PEG20 yielded additive antitumor effects as compared with either agent alone. Taken together, our findings offer mechanistic insight into arginine deprivation metabolism and ADI resistance, and they illustrate how combining inhibitors of the Ras\/ERK and PI3K\/AKT signaling pathways may improve ADI-PEG20 anticancer responses. Cancer Res; 72(10); 2622\u201333. \u00a92012 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-11-3605","type":"journal-article","created":{"date-parts":[[2012,3,29]],"date-time":"2012-03-29T20:32:28Z","timestamp":1333053148000},"page":"2622-2633","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":202,"title":["Activation of Ras\/PI3K\/ERK Pathway Induces c-Myc Stabilization to Upregulate Argininosuccinate Synthetase, Leading to Arginine Deiminase Resistance in Melanoma Cells"],"prefix":"10.1158","volume":"72","author":[{"given":"Wen-Bin","family":"Tsai","sequence":"first","affiliation":[{"name":"Authors' Affiliations: Departments of 1Molecular Pathology and 2Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 3Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isamu","family":"Aiba","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Molecular Pathology and 2Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 3Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Long","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Molecular Pathology and 2Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 3Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Kuan","family":"Lin","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Molecular Pathology and 2Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 3Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Feun","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Molecular Pathology and 2Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 3Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niramol","family":"Savaraj","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Molecular Pathology and 2Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 3Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macus Tien","family":"Kuo","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Molecular Pathology and 2Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 3Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2012,5,14]]},"reference":[{"key":"2022061702450930400_bib1","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s00262-011-1079-2","article-title":"Combination of targeted therapy and immunotherapy in melanoma","volume":"60","author":"Blank","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"2022061702450930400_bib2","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nature05661","article-title":"Melanoma biology and new targeted therapy","volume":"445","author":"Gray-Schopfer","year":"2007","journal-title":"Nature"},{"key":"2022061702450930400_bib3","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1586\/14737140.8.5.707","article-title":"Topoisomerase I inhibitors for the treatment of brain tumors","volume":"8","author":"Feun","year":"2008","journal-title":"Expert Rev Anticancer Ther"},{"key":"2022061702450930400_bib4","doi-asserted-by":"crossref","first-page":"246","DOI":"10.18632\/oncotarget.135","article-title":"Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes","volume":"1","author":"Kuo","year":"2010","journal-title":"Oncotarget"},{"key":"2022061702450930400_bib5","doi-asserted-by":"crossref","first-page":"7660","DOI":"10.1200\/JCO.2005.02.0933","article-title":"Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies","volume":"23","author":"Ascierto","year":"2005","journal-title":"J Clin Oncol"},{"key":"2022061702450930400_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2007.11.038","article-title":"Arginine deiminase, a potential anti-tumor drug","volume":"261","author":"Ni","year":"2008","journal-title":"Cancer Lett"},{"key":"2022061702450930400_bib7","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/0008-5472.CAN-06-1945","article-title":"Pegylated recombinant human arginase (rhArg-peg5,000 mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion","volume":"67","author":"Cheng","year":"2007","journal-title":"Cancer Res"},{"key":"2022061702450930400_bib8","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1200\/JCO.2004.11.120","article-title":"Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I\/II studies","volume":"22","author":"Izzo","year":"2004","journal-title":"J Clin Oncol"},{"key":"2022061702450930400_bib9","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1158\/1535-7163.MCT-09-0794","article-title":"Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc\/HIF-1alpha\/Sp4","volume":"8","author":"Tsai","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"2022061702450930400_bib10","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.onc.1205117","article-title":"Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling","volume":"21","author":"Kuo","year":"2002","journal-title":"Oncogene"},{"key":"2022061702450930400_bib11","first-page":"3235","article-title":"Inhibition of NIH 3T3 cell proliferation by a mutant ras protein with preferential affinity for GDP","volume":"8","author":"Feig","year":"1988","journal-title":"Mol Cell Biol"},{"key":"2022061702450930400_bib12","doi-asserted-by":"crossref","first-page":"19929","DOI":"10.1074\/jbc.273.32.19929","article-title":"Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase\/Akt cell survival pathway","volume":"273","author":"Pap","year":"1998","journal-title":"J Biol Chem"},{"key":"2022061702450930400_bib13","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.cell.2006.06.039","article-title":"A role for the deubiquitinating enzyme USP28 in control of the DNA-damage response","volume":"126","author":"Zhang","year":"2006","journal-title":"Cell"},{"key":"2022061702450930400_bib14","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1161\/01.RES.0000195656.52760.30","article-title":"PTEN activity is modulated during ischemia and reperfusion: involvement in the induction and decay of preconditioning","volume":"97","author":"Cai","year":"2005","journal-title":"Circ Res"},{"key":"2022061702450930400_bib15","doi-asserted-by":"crossref","first-page":"e11171","DOI":"10.1371\/journal.pone.0011171","article-title":"Inhibition of FOXO3 tumor suppressor function by betaTrCP1 through ubiquitin-mediated degradation in a tumor mouse model","volume":"5","author":"Tsai","journal-title":"PLoS One 2010"},{"key":"2022061702450930400_bib16","first-page":"2486","article-title":"Proteins encoded by the human c-myc oncogene: differential expression in neoplastic cells","volume":"4","author":"Hann","year":"1984","journal-title":"Mol Cell Biol"},{"key":"2022061702450930400_bib17","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/emboj\/18.3.717","article-title":"Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc","volume":"18","author":"Salghetti","year":"1999","journal-title":"EMBO J"},{"key":"2022061702450930400_bib18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/B978-0-12-386469-7.00004-9","article-title":"Proteolytic control of the oncoprotein transcription factor Myc","volume":"110","author":"Thomas","year":"2010","journal-title":"Adv Cancer Res"},{"key":"2022061702450930400_bib19","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/sj.emboj.7600217","article-title":"Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7","volume":"23","author":"Yada","year":"2004","journal-title":"EMBO J"},{"key":"2022061702450930400_bib20","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/ncb1601","article-title":"The ubiquitin-specific protease USP28 is required for MYC stability","volume":"9","author":"Popov","year":"2007","journal-title":"Nat Cell Biol"},{"key":"2022061702450930400_bib21","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1101\/gad.836800","article-title":"Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability","volume":"14","author":"Sears","year":"2000","journal-title":"Genes Dev"},{"key":"2022061702450930400_bib22","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.4161\/cc.3.9.1145","article-title":"The life cycle of C-myc: from synthesis to degradation","volume":"3","author":"Sears","year":"2004","journal-title":"Cell Cycle"},{"key":"2022061702450930400_bib23","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0960-9822(02)70790-2","article-title":"Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells","volume":"6","author":"Stambolic","year":"1996","journal-title":"Curr Biol"},{"key":"2022061702450930400_bib24","doi-asserted-by":"crossref","first-page":"13375","DOI":"10.1074\/jbc.273.22.13375","article-title":"The tumor suppressor, PTEN\/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate","volume":"273","author":"Maehama","year":"1998","journal-title":"J Biol Chem"},{"key":"2022061702450930400_bib25","first-page":"M21","article-title":"The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling","volume":"1470","author":"Vazquez","year":"2000","journal-title":"Biochim Biophys Acta"},{"key":"2022061702450930400_bib26","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1080\/01635580802521338","article-title":"Sodium selenite increases the activity of the tumor suppressor protein, PTEN, in DU-145 prostate cancer cells","volume":"61","author":"Berggren","year":"2009","journal-title":"Nutr Cancer"},{"key":"2022061702450930400_bib27","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1158\/0008-5472.CAN-09-4355","article-title":"Drugging the PI3 kinome: from chemical tools to drugs in the clinic","volume":"70","author":"Workman","year":"2010","journal-title":"Cancer Res"},{"key":"2022061702450930400_bib28","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1371\/journal.pbio.1000017","article-title":"Role of a novel PH-kinase domain interface in PKB\/Akt regulation: structural mechanism for allosteric inhibition","volume":"7","author":"Calleja","year":"2009","journal-title":"PLoS Biol"},{"key":"2022061702450930400_bib29","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s11912-009-0016-4","article-title":"Perifosine: update on a novel Akt inhibitor","volume":"11","author":"Gills","year":"2009","journal-title":"Curr Oncol Rep"},{"key":"2022061702450930400_bib30","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1101\/gad.1067003","article-title":"Genomic targets of the human c-Myc protein","volume":"17","author":"Fernandez","year":"2003","journal-title":"Genes Dev"},{"key":"2022061702450930400_bib31","doi-asserted-by":"crossref","first-page":"8164","DOI":"10.1073\/pnas.1332764100","article-title":"A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells","volume":"100","author":"Li","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061702450930400_bib32","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ccr.2007.07.006","article-title":"HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation","volume":"12","author":"Gordan","year":"2007","journal-title":"Cancer Cell"},{"key":"2022061702450930400_bib33","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1158\/0008-5472.CAN-10-3776","article-title":"MYC and metastasis","volume":"71","author":"Wolfer","year":"2011","journal-title":"Cancer Res"},{"key":"2022061702450930400_bib34","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.4161\/cc.6.19.4804","article-title":"Fbw7 and Usp28 regulate myc protein stability in response to DNA damage","volume":"6","author":"Popov","year":"2007","journal-title":"Cell Cycle"},{"key":"2022061702450930400_bib35","doi-asserted-by":"crossref","first-page":"E699","DOI":"10.1073\/pnas.1108237108","article-title":"PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis","volume":"108","author":"Ilic","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061702450930400_bib36","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nchembio.695","article-title":"A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer","volume":"7","author":"Muellner","year":"2011","journal-title":"Nat Chem Biol"},{"key":"2022061702450930400_bib37","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/nm.2402","article-title":"Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms","volume":"17","author":"Liu","year":"2011","journal-title":"Nat Med"},{"key":"2022061702450930400_bib38","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/sj.bjc.6601894","article-title":"The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website","volume":"91","author":"Bamford","year":"2004","journal-title":"Br J Cancer"},{"key":"2022061702450930400_bib39","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1517\/13543784.2011.562192","article-title":"New phosphatidylinositol 3-kinase inhibitors for cancer","volume":"20","author":"Bowles","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"2022061702450930400_bib40","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1517\/13543784.2010.520701","article-title":"Akt inhibitors in clinical development for the treatment of cancer","volume":"19","author":"Pal","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"2022061702450930400_bib41","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nm.2323","article-title":"Cancer genomics: from discovery science to personalized medicine","volume":"17","author":"Chin","year":"2011","journal-title":"Nat Med"},{"key":"2022061702450930400_bib42","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"key":"2022061702450930400_bib43","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"key":"2022061702450930400_bib44","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/nature09627","article-title":"COT drives resistance to RAF inhibition through MAP kinase pathway reactivation","volume":"468","author":"Johannessen","year":"2010","journal-title":"Nature"},{"key":"2022061702450930400_bib45","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ccr.2010.11.023","article-title":"Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R\/PI3K","volume":"18","author":"Villanueva","year":"2010","journal-title":"Cancer Cell"},{"key":"2022061702450930400_bib46","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1475-2867-9-9","article-title":"Pegylated derivatives of recombinant human arginase (rhArg1) for sustained in vivo activity in cancer therapy: preparation, characterization and analysis of their pharmacodynamics in vivo and in vitro and action upon hepatocellular carcinoma cell (HCC)","volume":"9","author":"Tsui","year":"2009","journal-title":"Cancer Cell Int"},{"key":"2022061702450930400_bib47","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/CAD.0b013e32834ae42b","article-title":"Cytotoxicity of human recombinant arginase I (Co)-PEG5000 in the presence of supplemental L-citrulline is dependent on decreased argininosuccinate synthetase expression in human cells","volume":"23","author":"Agrawal","year":"2011","journal-title":"Anticancer Drugs"},{"key":"2022061702450930400_bib48","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1755-148X.2010.00798.x","article-title":"Recombinant human arginase inhibits the in vitro and in vivo proliferation of human melanoma by inducing cell cycle arrest and apoptosis","volume":"24","author":"Lam","year":"2010","journal-title":"Pigment Cell Melanoma Res"},{"key":"2022061702450930400_bib49","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1021\/cb900267j","article-title":"Replacing Mn(2+) with Co(2+) in human arginase i enhances cytotoxicity toward l-arginine auxotrophic cancer cell lines","volume":"5","author":"Stone","year":"2010","journal-title":"ACS Chem Biol"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/72\/10\/2622\/2666904\/2622.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/72\/10\/2622\/2666904\/2622.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T07:17:01Z","timestamp":1655450221000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/72\/10\/2622\/575471\/Activation-of-Ras-PI3K-ERK-Pathway-Induces-c-Myc"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,14]]},"references-count":49,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2012,5,14]]},"published-print":{"date-parts":[[2012,5,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-11-3605","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,14]]}}}